Investing.comCodex · 实盘不做把握 3/10
北京时间·🕒 发布 04:16:55时区推断·⟳ 抓取 04:18:42·⚡ 决策 07-28 04:19:27 +45s·91.6 天前
Scribe Therapeutics完成1.555亿美元IPO及Sanofi同步私募认购
本次消息是IPO交割完成及承销商超额配售权全额行使，属于上市流程的程序性落地，不是新增经营订单、临床数据或监管批准。
📄 原文Investing.com↗ 原文
Scribe Therapeutics closes $155.5M IPO at $15 per share
Stocks end mixed to kick off key week dominated by mega-cap earnings, Fed decision ALAMEDA, Calif. - Scribe Therapeutic…
不做 Scribe Therapeutics（SCTX.US）
IPO交割完成属于程序性上市流程，股票已开始交易，未披露新增临床、监管、订单或商业化增量；缺少可执行的短线正期望，不做。
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
🔎 新鲜度:最早出现 2026-07-27 · 扩散 medium · price-in 风险 high ↗
关键理由
- 本次消息是IPO交割完成及承销商超额配售权全额行使，属于上市流程的程序性落地，不是新增经营订单、临床数据或监管批准。
- Sanofi按IPO价参与50万股同步私募属于已随发行披露的融资结构信息，未给出新合作金额、里程碑或产品商业化增量。
- 公司虽有CRISPR管线和大药企合作背景，但该信号本身无法形成短周期同向交易催化。
主要风险
- 新股上市早期波动主要由流动性、锁定期和风险偏好驱动，IPO交割新闻难以提供可回测的正期望边界。
原文全文
展开原文 · 1,769 字
Stocks end mixed to kick off key week dominated by mega-cap earnings, Fed decision
ALAMEDA, Calif. - Scribe Therapeutics Inc. (NASDAQ:SCTX) completed its initial public offering today, selling 9,867,000 shares of common stock at $15.00 per share, according to a press release statement.
The offering included the full exercise of the underwriters’ option to purchase 1,287,000 additional shares. The company’s common stock began trading on the Nasdaq Global Market on Thursday under the ticker symbol SCTX.
The aggregate gross proceeds from the IPO totaled approximately $155.51 million before deducting underwriting discounts and commissions. This figure includes proceeds from a concurrent private placement.
Scribe Therapeutics also closed a concurrent private placement today, selling 500,000 shares of common stock to Sanofi at the IPO price per share. The private placement shares were not registered under the Securities Act of 1933.
Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities and Wells Fargo Securities served as joint book-running managers for the offering.
The registration statement relating to the securities became effective on July 23, 2026, and a prospectus has been filed with the U.S. Securities and Exchange Commission.
Scribe Therapeutics is a clinical-stage biotechnology company developing CRISPR-based technologies for genetic medicines. The company’s lead candidate, STX-1150, is a liver-targeted therapy designed to silence the PCSK9 gene and reduce LDL-C levels.
The company has formed strategic collaborations with Sanofi and Eli Lilly. Scribe Therapeutics was co-founded by Nobel Prize winner Jennifer Doudna.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
ALAMEDA, Calif. - Scribe Therapeutics Inc. (NASDAQ:SCTX) completed its initial public offering today, selling 9,867,000 shares of common stock at $15.00 per share, according to a press release statement.
The offering included the full exercise of the underwriters’ option to purchase 1,287,000 additional shares. The company’s common stock began trading on the Nasdaq Global Market on Thursday under the ticker symbol SCTX.
The aggregate gross proceeds from the IPO totaled approximately $155.51 million before deducting underwriting discounts and commissions. This figure includes proceeds from a concurrent private placement.
Scribe Therapeutics also closed a concurrent private placement today, selling 500,000 shares of common stock to Sanofi at the IPO price per share. The private placement shares were not registered under the Securities Act of 1933.
Leerink Partners, Goldman Sachs & Co. LLC, Guggenheim Securities and Wells Fargo Securities served as joint book-running managers for the offering.
The registration statement relating to the securities became effective on July 23, 2026, and a prospectus has been filed with the U.S. Securities and Exchange Commission.
Scribe Therapeutics is a clinical-stage biotechnology company developing CRISPR-based technologies for genetic medicines. The company’s lead candidate, STX-1150, is a liver-targeted therapy designed to silence the PCSK9 gene and reduce LDL-C levels.
The company has formed strategic collaborations with Sanofi and Eli Lilly. Scribe Therapeutics was co-founded by Nobel Prize winner Jennifer Doudna.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
这条决策早于决策账本(2026-10-08 起逐条追加),没有追加记录。